Study of HS-10504 combination for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug combination for people with advanced non-small cell lung cancer (NSCLC) that has a specific gene change (EGFR mutation or MET-positive) and has worsened after prior treatment. It aims to see if the combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced NSCLC with either an EGFR mutation or MET-positive status and your cancer has grown after prior treatment.
- You have at least one tumor that can be measured on scans.
- You are able to take care of yourself (ECOG score 0-1) and are expected to live at least 12 more weeks.
- Your organs are working well enough (based on blood tests).
- You agree to use effective birth control if you could become pregnant or father a child, and women must not breastfeed during the study and for 6 months after.
- You have not had certain other cancers, brain metastases, or serious health issues like heart disease, poorly controlled diabetes, or active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new drug combination (HS-20122) for non-small cell lung cancer that has spread or cannot be surgically removed. You may qualify if your cancer has progressed despite prior treatment or you haven't received prior treatment yet.
This trial tests a new drug, HRS-4508, given with other cancer treatments for people with advanced non-small cell lung cancer whose previous treatments have failed. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a new targeted drug (HS-10504) for people with advanced EGFR-mutated non-small cell lung cancer that has worsened after previous EGFR inhibitor therapy. The study aims to see if this drug can help shrink tumors or slow cancer growth.
This Phase 1/2 trial tests HS-10375, a study drug, in people with advanced or metastatic non-small-cell lung cancer (NSCLC) whose cancer has a specific EGFR mutation (C797S). It may help by targeting that mutation when standard treatments are not an option.
This trial tests a new drug, HSK40118, for people with advanced non-small cell lung cancer (NSCLC) that has an EGFR mutation and has been treated with certain EGFR-targeted therapies before. The goal is to see if this drug can help when other treatments stop working.
This trial tests a combination of two new drugs (SHR-A1811 and AK112) for people with a specific type of advanced lung cancer that has changes in the HER2 gene. It may help those whose cancer has gotten worse after one previous treatment, or who have not yet had any treatment for advanced disease.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.